Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1998 1
2002 1
2007 3
2008 1
2010 2
2011 1
2012 2
2015 3
2017 1
2018 4
2019 3
2023 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory WHO Grade 2 Glioma"
Page 1
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M. Fangusaro J, et al. Lancet Oncol. 2019 Jul;20(7):1011-1022. doi: 10.1016/S1470-2045(19)30277-3. Epub 2019 May 28. Lancet Oncol. 2019. PMID: 31151904 Free PMC article. Clinical Trial.
We aimed to assess the activity of selumetinib, a MEK1/2 inhibitor, in these patients. METHODS: The Pediatric Brain Tumor Consortium performed a multicentre, phase 2 study in patients with paediatric low-grade glioma in 11 hospitals in the USA. ...Stra …
We aimed to assess the activity of selumetinib, a MEK1/2 inhibitor, in these patients. METHODS: The Pediatric Brain Tumor Consortium …
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I. Peyrl A, et al. JAMA Oncol. 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. JAMA Oncol. 2023. PMID: 37883081 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: This phase 2, investigator-initiated, multicenter nonrandomized controlled trial assessed 40 patients with relapsed or refractory medulloblastoma without a ventriculoperitoneal shunt who were younger than 20 years at original diagn …
DESIGN, SETTING, AND PARTICIPANTS: This phase 2, investigator-initiated, multicenter nonrandomized controlled trial assessed 40 patie …
Phase I study of non-pegylated liposomal doxorubicin in children with recurrent/refractory high-grade glioma.
Chastagner P, Devictor B, Geoerger B, Aerts I, Leblond P, Frappaz D, Gentet JC, Bracard S, André N. Chastagner P, et al. Cancer Chemother Pharmacol. 2015 Aug;76(2):425-32. doi: 10.1007/s00280-015-2781-0. Epub 2015 Jun 27. Cancer Chemother Pharmacol. 2015. PMID: 26115930 Clinical Trial.
METHODS: Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radiotherapy but no anthracyclines. ...RESULTS: Between October 2010 and January 2013, 13 children aged 6-17 years were treated. In total, 27 …
METHODS: Eligible patients were children with refractory high-grade glioma who had received prior chemotherapy and radi …
Survival outcome and predictors of WHO grade 2 and 3 insular gliomas: A classification based on the tumor spread.
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J. Xue B, et al. Cancer Med. 2024 Jun;13(11):e7377. doi: 10.1002/cam4.7377. Cancer Med. 2024. PMID: 38850123 Free PMC article.
OBJECTIVE: The study aimed to identify if clinical features and survival outcomes of insular glioma patients are associated with our classification based on the tumor spread. METHODS: Our study included 283 consecutive patients diagnosed with histological grade 2 …
OBJECTIVE: The study aimed to identify if clinical features and survival outcomes of insular glioma patients are associated with our …
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S. Bouffet E, et al. J Clin Oncol. 2012 Apr 20;30(12):1358-63. doi: 10.1200/JCO.2011.34.5843. Epub 2012 Mar 5. J Clin Oncol. 2012. PMID: 22393086 Clinical Trial.
PURPOSE: To evaluate the efficacy of single-agent vinblastine in pediatric patients with recurrent or refractory low-grade glioma. PATIENTS AND METHODS: Patients were eligible if they had experienced previous treatment failure (chemotherapy and/or radiation) …
PURPOSE: To evaluate the efficacy of single-agent vinblastine in pediatric patients with recurrent or refractory low-grade …
Confirmation of Bevacizumab Activity, and Maintenance of Efficacy in Retreatment After Subsequent Relapse, in Pediatric Low-grade Glioma.
Kalra M, Heath JA, Kellie SJ, Dalla Pozza L, Stevens MM, Swamy S, McCowage GB. Kalra M, et al. J Pediatr Hematol Oncol. 2015 Aug;37(6):e341-6. doi: 10.1097/MPH.0000000000000371. J Pediatr Hematol Oncol. 2015. PMID: 26056795
BACKGROUND: Management of low-grade gliomas (LGG) can be a challenge, particularly when not resectable and refractory or recurrent following standard treatments. We undertook a retrospective analysis of 2 institutions' experiences treating children for …
BACKGROUND: Management of low-grade gliomas (LGG) can be a challenge, particularly when not resectable and refractory o …
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Lassman AB, et al. Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091. Neuro Oncol. 2019. PMID: 29982805 Free PMC article. Clinical Trial.
BACKGROUND: Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). ...Antitumor activity in this TMZ-refractory population was encouraging. Continued study of depatux-m in patien …
BACKGROUND: Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recu …
Low-grade glial neoplasms and intractable partial epilepsy: efficacy of surgical treatment.
Britton JW, Cascino GD, Sharbrough FW, Kelly PJ. Britton JW, et al. Epilepsia. 1994 Nov-Dec;35(6):1130-5. doi: 10.1111/j.1528-1157.1994.tb01778.x. Epilepsia. 1994. PMID: 7988500
We performed a retrospective study of 51 consecutive patients who underwent operation for intractable partial epilepsy related to low-grade intracerebral neoplasms between 1984 and 1990. All patients had medically refractory partial seizures and a mass lesion identi …
We performed a retrospective study of 51 consecutive patients who underwent operation for intractable partial epilepsy related to low-gra …
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Kong DS, Lee JI, Kim JH, Kim ST, Kim WS, Suh YL, Dong SM, Nam DH. Kong DS, et al. Neuro Oncol. 2010 Mar;12(3):289-96. doi: 10.1093/neuonc/nop030. Epub 2010 Jan 11. Neuro Oncol. 2010. PMID: 20167817 Free PMC article. Clinical Trial.
This phase II trial included 2 cohorts of patients. The initial cohort, comprising 10 patients, received TMZ at 40 mg/m(2) everyday. ...The 6-month progression-free survival in all 38 patients was 32.5% (95% CI: 29.3%-35.8%) and the 6-month overall survival was 56.0 …
This phase II trial included 2 cohorts of patients. The initial cohort, comprising 10 patients, received TMZ at 40 mg/m(2) eve …
Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas.
Yerram P, Reiss SN, Modelevsky L, Gavrilovic IT, Kaley T. Yerram P, et al. J Neurooncol. 2019 Oct;145(1):57-63. doi: 10.1007/s11060-019-03266-0. Epub 2019 Aug 20. J Neurooncol. 2019. PMID: 31432377 Free PMC article. Clinical Trial.
PURPOSE: An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with recurrent or progressive high grade gliomas (HGG). Data regarding incidence of toxicity with combination bevacizumab and carmust …
PURPOSE: An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with re …
24 results